Amgen (AMGN) EVP James Bradner logs two F-coded stock disposals

Rhea-AI Filing Summary

Amgen Inc. executive James E. Bradner, EVP, Research and Development, reported two dispositions of Amgen common stock in transactions coded F on February 9, 2026. The Form 4 shows 2,151 shares and 953 shares disposed of at $384.32 per share in separate entries.

After these transactions, the reported directly owned balances were 28,331 shares and 27,378 shares in the respective lines. The holdings include 1,205 dividend equivalents granted under Amgen’s 2009 Equity Incentive Plan, which are paid out in shares on a one-to-one basis as related RSUs vest.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Bradner James E.

Role EVP, Research and Development

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	2,151	$384.32	$827K
Tax Withholding	Common Stock	953	$384.32	$366K

Holdings After Transaction: Common Stock — 28,331 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bradner James E.

(Last) (First) (Middle)

ONE AMGEN CENTER DRIVE

(Street)

THOUSAND OAKS CA 91320

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AMGEN INC [ AMGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Research and Development

3. Date of Earliest Transaction (Month/Day/Year)
02/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/09/2026		F		2,151	D	$384.32	28,331	D
Common Stock	02/09/2026		F		953	D	$384.32	27,378(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares include 1,205 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

	/s/ James E. Bradner	02/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Amgen (AMGN) EVP James E. Bradner report on this Form 4?

James E. Bradner reported two dispositions of Amgen common stock on February 9, 2026. Each transaction is coded F and involved 2,151 and 953 shares, respectively, at a price of $384.32 per share, as shown in the filing’s non-derivative table.

How many Amgen (AMGN) shares does James E. Bradner own after the reported Form 4 transactions?

After the February 9, 2026 transactions, the Form 4 shows directly owned balances of 28,331 shares and 27,378 shares in the respective line items. These reported amounts reflect Bradner’s beneficial ownership following each disposition entry in the non-derivative securities table.

What does transaction code F indicate in James E. Bradner’s Amgen (AMGN) Form 4 filing?

Both reported Amgen transactions for James E. Bradner use transaction code F. The Form 4 labels this code in the transaction code column, indicating the specific type of disposition being reported for each line item in the non-derivative securities section.

At what price were the Amgen (AMGN) shares in James E. Bradner’s Form 4 transactions reported?

Each reported transaction in the Form 4 lists a price of $384.32 per Amgen common share. This price applies to both dispositions coded F on February 9, 2026, as disclosed in the non-derivative securities table of the filing.

What are the 1,205 dividend equivalents mentioned in the Amgen (AMGN) Form 4 footnote?

The Form 4 footnote states Bradner’s holdings include 1,205 dividend equivalents granted under Amgen’s 2009 Equity Incentive Plan. These dividend equivalents are credited on unvested RSUs and paid in Amgen common stock on a one-to-one basis as the RSUs vest, plus cash for fractional amounts.

How are dividend equivalents (DEs) on Amgen (AMGN) RSUs paid to James E. Bradner?

According to the footnote, dividend equivalents on Bradner’s unvested RSUs are paid out in shares of Amgen common stock on a one-to-one basis. Any remaining fractional share amounts are settled in cash, following the vesting schedule of the underlying restricted stock units.